Developing Optimal Formulations Using Biorelevant Predictive Tools and Advanced Bioavailability Enhancement Technologies
Summary: An increasing number of new chemical entities (NCEs) present with bioavailability issues. Low bioavailability is associated with increased pharmacokinetic variability in both preclinical species and humans, which can lead to additional development challenges. Advanced formulation expertise and technologies are needed to reduce risk early on and achieve a viable formulation, thus increasing the chance of success in the clinic.